The short version of lactam bridge fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-09. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
== Availability == In part thanks to the wide range of similar PSMA radiopharmaceuticals, approval by regulatory authorities is at varying stages. Even so, use has been widespread in some areas, particularly as part of clinical trials. For example, European Association of Urology (EAU) guidelines have included recommendations to perform PSMA PET scans in certain circumstances since 2018, and there has been widespread agreement of the utility of PSMA scanning for several years.
[as having] in common one predominating trait and that was a love of the woods and all wild things. Lore, though he loved to fish, called for a camera rather than a gun, and I believe a camera and a fishhook have always remained his only weapons. He early developed a liking for research which finally became his speciality. Lore, like his other siblings including Lou Rogers, attended the Patten Academy, which graduated a number of highly successful individuals. He entered the University of Maine, joined its first football team, and pledged Kappa Sigma. He earned a B. S. in agriculture in 1896, especially appreciating the one course that was offered in the new science of bacteriology. Years later the campus dairy industry building would be named in his honor. Rogers returned home to spend a season as clerk and assistant in his father's lumbering operations. He also used his photography skills to capture the experience and perils of woodsmen's lives. He was then inspired to pursue bacteriology, selecting the University of Wisconsin, which had opened the first American school of dairy science seven years earlier. He was privileged to study under Harry Luman Russell, a noted bacteriologist who earned an early PhD in that field at Johns Hopkins University. Lore Rogers remained at Wisconsin for the year 1897-1898, during which time, in addition to his studies, he helped found the Beta-Epsilon chapter of Kappa Sigma.
== Other uses == G-TELP, an English language test Girmit Soccer Tournament, afootball tournament in Fiji Grand Slam Track, a professional track and field league Grand Southern Trunk Road, in India Greystone (CIA operation), a former secret codeword relating to counter-terrorism programs of the CIA after 9/11 Gustavus Airport, in Alaska
=== Chemical precursor === A number of useful compounds are made from acrolein, exploiting its bifunctionality. The amino acid methionine is produced by addition of methanethiol followed by the Strecker synthesis. Acrolein condenses with acetaldehyde and amines to give methylpyridines. It is also an intermediate in the Skraup synthesis of quinolines. Acrolein will polymerize in the presence of oxygen and in water at concentrations above 22%. The color and texture of the polymer depends on the conditions. The polymer is a clear, yellow solid. In water, it will form a hard, porous plastic. Acrolein has been used as a fixative in preparation of biological specimens for electron microscopy.
Sources: en.wikipedia.org
subsequently found that HClO destroys cytochromes and iron-sulfur clusters and observed that oxygen uptake is abolished by HClO and adenine nucleotides are lost. It was also observed that irreversible oxidation of cytochromes paralleled the loss of respiratory activity. One way of addressing the loss of oxygen uptake was by studying the effects of HClO on succinate-dependent electron transport. Rosen et al. found that levels of reductable cytochromes in HClO-treated cells were normal, and these cells were unable to reduce them. Succinate dehydrogenase was also inhibited by HClO, stopping the flow of electrons to oxygen. Later studies revealed that Ubiquinol oxidase activity ceases first, and the still-active cytochromes reduce the remaining quinone. The cytochromes then pass the electrons to oxygen, which explains why the cytochromes cannot be reoxidized, as observed by Rosen et al. However, this line of inquiry was ended when Albrich et al. found that cellular inactivation precedes loss of respiration by using a flow mixing system that allowed evaluation of viability on much smaller time scales. This group found that cells capable of respiring could not divide after exposure to HClO.
==== India ==== The Department of Information Technology created the Indian Computer Emergency Response Team (CERT-In) in 2004 to thwart cyber attacks in India. That year, there were 23 reported cyber security breaches. In 2011, there were 13,301. That year, the government created a new subdivision, the National Critical Information Infrastructure Protection Centre (NCIIPC) to thwart attacks against energy, transport, banking, telecom, defense, space and other sensitive areas. The executive director of the Nuclear Power Corporation of India (NPCIL) stated in February 2013 that his company alone was forced to block up to ten targeted attacks a day. CERT-In was left to protect less critical sectors. A high-profile cyber attack on 12 July 2012 breached the email accounts of about 12,000 people, including those of officials from the Ministry of External Affairs, Ministry of Home Affairs, Defense Research and Development Organizations (DRDO), and the Indo-Tibetan Border Police (ITBP). A government-private sector plan being overseen by National Security Advisor (NSA) Shivshankar Menon began in October 2012, and intends to boost up India's cyber security capabilities in the light of a group of experts findings that India faces a 470,000 shortfall of such experts despite the country's reputation of being an IT and software powerhouse. In February 2013, Information Technology Secretary J. Satyanarayana stated that the NCIIPC was finalizing policies related to national cyber security that would focus on domestic security solutions, reducing exposure through foreign technology.
== P == Pier Paolo Pandolfi (b. 1963). Italian geneticist and molecular biologist at the Desert Research Institute, Reno, known for work on pseudogenes. Jakub Karol Parnas (1884–1949). Polish-Soviet biochemist at the University of Lviv, who discovered (with Gustav Embden and Otto Fritz Meyerhof), the glycolytic pathway. Linus Pauling (1901–1994). American chemist and biochemist at Caltech, known for many advances in chemistry, including the α-helical structure of proteins. Nobel Prize in Chemistry (1954). Louis Pasteur FRS (foreign associate) (1822–1895). French biologist, microbiologist and chemist at the Pasteur Institute (Paris), who made many contributions to microbiology, stereochemistry and medicine, including the first vaccines for rabies and anthrax. Natl. Acad. Sci. USA (foreign associate). Arthur Peacocke (1924–2006). British Anglican theologian and biochemist at the University of Oxford. Max Perutz FRS (1914–2002). Austrian-British molecular biologist and X-ray crystallographer at Cambridge University, who solved the crystal structure of haemoglobin. Nobel Prize in Chemistry (1962). Samuel Victor Perry FRS (1918–2009). British biochemist at the University of Birmingham, pioneer in the biochemistry of muscle. Gösta Pettersson (b. 1937). Swedish biochemist at the University of Lund, expert on enzyme kinetics. Antoinette Pirie (1905–1991), British biochemist, ophthalmologist, and educator. Norman Wingate Pirie FRS (1907–1997), British biochemist and virologist. Rosalind Pitt-Rivers (1907–1990).
The medication is used to treat clear cell renal cell carcinoma, the most common histological subtype. The treatment phase is continuing treatment beyond three months. The patient has been issued an authority prescription for pazopanib. The patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST). This treatment must be the sole tyrosine kinase inhibitor subsidised for this condition. Pazopanib has also demonstrated initial therapeutic properties in patients with aggressive fibromatosis (desmoid tumor), ovarian and non-small cell lung cancer. However, plans to apply to the EMA for a variation to include advanced ovarian cancer have been withdrawn and a license will not be sought in any country.
=== Drug–drug interactions with siRNA therapeutics === As the number of approved RNAi therapeutics has grown, reaching seven in 2025 (patisiran, givosiran, lumasiran, inclisiran, vutrisiran, nedosiran, and fitusiran), a distinct challenge has emerged in assessing drug–drug interactions (DDIs) for this drug class. Unlike small-molecule drugs, siRNA therapeutics are not major substrates of cytochrome P450 enzymes and do not rely on classical hepatic or renal uptake transporters. Instead, they are metabolized by endogenous endo- and exonucleases to shortened oligonucleotide chains, and their systemic pharmacokinetic parameters often do not reflect target-tissue distribution or pharmacodynamic (PD) outcomes. A clinically observed example of an unexpected DDI is givosiran, which produced a 2- to 3-fold increase in systemic exposure to cytochrome P450 substrates dextromethorphan (CYP2D6) and caffeine (CYP1A2) in patients with acute intermittent porphyria—an effect not predicted by standard in vitro CYP enzyme studies. The proposed mechanism involves indirect interference with hepatic heme biosynthesis via on-target suppression of aminolevulinate synthase 1 (ALAS1), rather than direct enzyme inhibition. More broadly, siRNA drugs may compete with endogenous microRNAs (miRNAs) for shared components of the RNA-induced silencing complex (RISC), particularly Argonaute (AGO) proteins.
Sources: en.wikipedia.org
== Clinical significance == Increasing evidence links aberrant CL metabolism and content to human disease. Human conditions include neurological disorders, cancer, and cardiovascular and metabolic disorders (a full list can be found at). As the number of human diseases with CL profile abnormalities has exponentially grown, the use of qualitative and quantitative diagnostics has emerged as a necessity.
The L-type amino acid transporter (LAT1) is a uniporter that mediates the transport of neutral amino acids like L-tryptophan, leucine, histidine, proline, alanine, etc. LAT1 favors the transport of amino acids with large branched or aromatic side chains. The amino acid transporter functions to move essential amino acids into the intestinal epithelium, placenta, and blood-brain barrier for cellular processes such as metabolism and cell signaling. The transporter is of particular significance in the central nervous system as it provides the necessary amino acids for protein synthesis and neurotransmitter production in brain cells. Aromatic amino acids like phenylalanine and tryptophan are precursors for neurotransmitters like dopamine, serotonin, and norepinephrine. LAT1 is a membrane protein of the SLC7 family of transporters and works in conjunction with the SLC3 family member 4F2hc to form a heterodimeric complex known as the 4F2hc complex. The heterodimer consists of a light chain and a heavy chain covalently bonded by a disulfide bond. The light chain is the one that carries out transport, while the heavy chain is needed to stabilize the dimer. There is some controversy over whether LAT1 is an uniporter or an antiporter. The transporter has uniporter characteristics of transporting amino acids into cells in a unidirectional manner down the concentration gradient. However, recently it has been found that the transporter has antiporter characteristics of exchanging neutral amino acids for abundant intracellular amino acids.
Woods assures Biko that he will meet with a Government official to discuss the matter. Woods then meets with Jimmy Kruger (John Thaw), the South African Minister of Justice, in his house in Pretoria in an attempt to prevent further abuses. Minister Kruger first expresses discontent over their actions; however, Woods is later harassed at his home by security forces, who insinuate that their orders came directly from Kruger. Later, Biko travels to Cape Town to speak at a student-run meeting. En route, security forces stop his car and arrest him asking him to say his name, and he says, "Bantu Stephen Biko". He is held in harsh conditions and beaten, causing a severe brain injury. A doctor recommends consulting a nearby specialist in order to best treat his injuries, but the police refuse out of fear that he might escape. The security forces instead decide to take him to a police hospital in Pretoria, around 700 miles (1,100 km) away from Cape Town. He is thrown into the back of a prison van and driven on a bumpy road, aggravating his brain injury and resulting in his death. Woods then works to expose the police's complicity in Biko's death. He attempts to expose photographs of Biko's body that contradict police reports that he died of a hunger strike, but he is prevented just before boarding a plane to leave and informed that he is now 'banned', therefore not able to leave the country.
Tillman Gerngross (born November 15, 1963) is an Austro-American scientist. He is a professor of bioengineering at the Thayer School of Engineering at Dartmouth College, and an adjunct professor in the departments of biology and chemistry at Dartmouth. Gerngross has been an active inventor and to date his work has resulted in the founding of multiple companies (GlycoFi, Inc., Adimab LLC, Arsanis, Inc., Alector [Nasdaq:ALEC], Avitide, Inc., Amagma, Inc., Ankyra, and Adagio [Nasdaq:ADGI]) and over a dozen U.S. and international patents. Gerngross was elected a member of the National Academy of Engineering in 2017.
Activated carbon can be manufactured from carbonaceous material, including coal (bituminous, subbituminous, and lignite), peat, wood, or nutshells (e.g., coconut). The manufacturing process consists of two phases: carbonization and activation. The carbonization process includes drying and then heating to separate by-products, including tars and other hydrocarbons from the raw material, as well as to drive off any gases generated. The process is completed by heating the material over 400 °C (750 °F) in an oxygen-free atmosphere that cannot support combustion. The carbonized particles are then "activated" by exposing them to an oxidizing agent, usually steam or carbon dioxide, at high temperature. This agent burns off the pore-blocking structures created during the carbonization phase, and so they develop a porous, three-dimensional graphite lattice structure. The size of the pores developed during activation is a function of the time that they spend in this stage. Longer exposure times result in larger pore sizes. The most popular aqueous phase carbons are bituminous based because of their hardness, abrasion resistance, pore size distribution, and low cost, but their effectiveness needs to be tested in each application to determine the optimal product. Activated carbon is used for adsorption of organic substances and non-polar adsorbates and it is also usually used for waste gas (and waste water) treatment. It is the most widely used adsorbent since most of its chemical (e.g. surface groups) and physical properties (e.g.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.